1.07
Schlusskurs vom Vortag:
$0.9933
Offen:
$1.05
24-Stunden-Volumen:
2.77M
Relative Volume:
3.50
Marktkapitalisierung:
$58.55M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.56M
KGV:
-0.9145
EPS:
-1.17
Netto-Cashflow:
$-35.28M
1W Leistung:
+28.42%
1M Leistung:
+0.94%
6M Leistung:
-18.94%
1J Leistung:
-31.85%
Pds Biotechnology Corporation Stock (PDSB) Company Profile
Firmenname
Pds Biotechnology Corporation
Sektor
Branche
Telefon
800-208-3343
Adresse
303A COLLEGE ROAD EAST, PRINCETON
Vergleichen Sie PDSB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
PDSB
Pds Biotechnology Corporation
|
1.07 | 54.35M | 0 | -40.56M | -35.28M | -1.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pds Biotechnology Corporation Stock (PDSB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-11-01 | Eingeleitet | B. Riley Securities | Buy |
| 2021-06-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-11-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-05-27 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-03-09 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-10-24 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Pds Biotechnology Corporation Aktie (PDSB) Neueste Nachrichten
PDS Biotechnology Corporation (PDSB) stock: surges as FDA protocol amendment aims for accelerated approval - parameter.io
PDS Biotech stock soars after FDA meeting provides accelerated approval path - Investing.com Canada
PDS Biotech Announces FDA Alignment on Use of Progression Free Survival as Primary Endpoint - MarketScreener
PDS Biotech submits amended protocol for phase 3 cancer trial By Investing.com - Investing.com India
PDS Biotech Files Amended Protocol for Phase 3 VERSATILE-003 Trial to Seek Accelerated Approval of PDS0101 - Quiver Quantitative
Cancer trial tweak could get a new head and neck treatment to patients faster - Stock Titan
How institutional buying supports PDS Biotechnology Corporation stockJuly 2025 Fed Impact & Free Reliable Trade Execution Plans - ulpravda.ru
Is PDS Biotechnology Corporation stock resilient to inflation2025 Earnings Impact & AI Forecasted Entry/Exit Points - ulpravda.ru
Does PDS Biotechnology Corporation stock trade at a discount to peersM&A Rumor & Verified Short-Term Trading Plans - ulpravda.ru
PDS Biotechnology (NASDAQ:PDSB) Trading 5% Higher – Here’s Why - Defense World
Aug Sentiment: How PDS Biotechnology Corporation stock trades during market volatility2025 Pullback Review & Entry and Exit Point Strategies - Улправда
How interest rate cuts could boost PDS Biotechnology Corporation stockSell Signal & Reliable Entry Point Alerts - Улправда
Guidance Update: Does PDS Biotechnology Corporation stock trade at a discount to peersMarket Volume Report & Verified Momentum Watchlists - Улправда
Can PDS Biotechnology Corporation stock sustain institutional interest2025 Pullback Review & Weekly Chart Analysis and Trade Guides - DonanımHaber
Will PDS Biotechnology Corporation stock continue upward momentum2025 Institutional Moves & Daily Market Momentum Tracking - bolumsonucanavari.com
How PDS Biotechnology Corporation stock performs after earningsJuly 2025 Update & Capital Efficiency Focused Ideas - DonanımHaber
Aug Spikes: How supply chain issues affect PDS Biotechnology Corporation stockWeekly Market Outlook & Real-Time Volume Trigger Notifications - moha.gov.vn
PDS Biotechnology (NASDAQ:PDSB) Shares Down 1.9% – Here’s What Happened - Defense World
Stocks of PDS Biotechnology Corporation (PDSB) are poised to climb above their peers - setenews.com
PDS Biotech secures new patent for cancer immunotherapy in Japan By Investing.com - Investing.com Australia
PDS Biotechnology Secures New Patent for PDS0101 - TipRanks
PDS Biotech secures new patent for cancer immunotherapy in Japan - Investing.com
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan - The Manila Times
PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why - sharewise.com
EPS Watch: How interest rate cuts could boost PDS Biotechnology Corporation stockTrade Risk Report & Precise Buy Zone Tips - moha.gov.vn
How supply chain issues affect PDS Biotechnology Corporation stock2025 Macro Impact & AI Powered Market Trend Analysis - Newser
A better buy-in window may exist right now for PDS Biotechnology Corporation (PDSB) - setenews.com
Is PDS Biotechnology Corporation stock ready for breakoutOptions Play & Real-Time Volume Spike Alerts - Newser
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration - marketscreener.com
PDS Biotech secures FDA meeting to discuss accelerated approval pathway By Investing.com - Investing.com Nigeria
PDS Biotech secures FDA meeting to discuss accelerated approval pathway - Investing.com
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration ('FDA”) - The Manila Times
PDS Biotech announces scheduling of Type C meeting with U.S. Food and Drug Administration - marketscreener.com
PDS Biotech (Nasdaq: PDSB) Plans FDA Talk on PFS Endpoint in VERSATILE-003 Trial - Stock Titan
Energy Moves: How interest rate cuts could boost PDS Biotechnology Corporation stock2025 Volatility Report & Capital Efficiency Focused Ideas - moha.gov.vn
Adversity is less terrifying than hope: PDS Biotechnology Corporation (PDSB) - Setenews
B. Riley Cuts PDS Biotechnology (NASDAQ:PDSB) Price Target to $3.00 - Defense World
History Review: How interest rate cuts could boost PDS Biotechnology Corporation stockPortfolio Growth Summary & Precise Buy Zone Tips - moha.gov.vn
PDS Biotechnology price target lowered to $3 from $5 at B. Riley - Yahoo Finance
B. Riley Securities Maintains PDS Biotechnology (PDSB) Buy Recommendation - Nasdaq
B. Riley Adjusts Price Target on PDS Biotechnology to $3 From $5, Maintains Buy Rating - marketscreener.com
Can PDS Biotechnology Corporation stock reach $100 price targetMarket Performance Report & Growth Focused Investment Plans - newser.com
PDS Biotechnology Shares Face Market Pressure Despite Clinical Promise - Ad-hoc-news.de
What dividend safety score for PDS Biotechnology Corporation stock2025 Market Overview & Real-Time Volume Analysis Alerts - newser.com
Why PDS Biotechnology Corporation stock is recommended by analysts2025 Top Decliners & Growth Focused Stock Reports - newser.com
Earnings visualization tools for PDS Biotechnology CorporationOil Prices & Verified Technical Signals - newser.com
PDS Biotechnology Corporation’s volatility index tracking explainedInflation Watch & Breakout Confirmation Alerts - newser.com
Advanced analytics toolkit walkthrough for PDS Biotechnology CorporationCPI Data & Daily Oversold Bounce Ideas - newser.com
Finanzdaten der Pds Biotechnology Corporation-Aktie (PDSB)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):